and our the Ollie. on call environment seeing results in our current quarter which the product general as We'll strategies we afternoon. utilization. aesthetic an our high trends space focus review as review and segment shared, segment core while the increased update miraDry provide you going our all previously on bioTip joining our we're as today. margin well thank breast We'll for our go-forward strategy, business then our Good Thanks, And first refocusing second on COVID-XX forward. has
discuss we'll and ahead. financial initiatives quarters the vision and ongoing Finally, our to flexibility maintain months our for
so of also I'd commitment patients. their continue are like teams, our the reiterate moving the and As all this and customers and prioritize many measures saying, and maintained of safety even family gratitude we our health of to earlier frontline to many the year workers enacted ensure the forward. our them to our for safety in our in others to bolstered We've health will partners, and Sientra everyone
has adapt to initiatives to operate corporate now we ability intend Our results. evolving quickly enabled proven landscape we move that second quarter to us ahead With of I'll the that currently to forward. forge our said, review to shift continue where critical with to
year. prior of impacted. Sientra net business felt XX% drive our over in most million, our mirror recorded The with second sales product decrease This a quarter decrease total less significantly breast was segments $XX.X acutely segment
attributable of both net recorded which a quarter breast COVID-XX includes which segment, $X.X decline, the second augmentation to is directly our reconstruction, year-over-year For and product sales XX% we million, pandemic.
year-on-year bioTip high second also and refocus achieve margin our is we a million, XX% which attributable sales COVID-XX we on quarter decline, For of miraDry decision sales. to pandemic the both believe miraDry, to $X.X net
strength strength the of miraDry these and adapting of a our approximately by physician well expectations drive within our historically businesses. the of and our the confidence bioTip to as in confirmed surgical customers this durability are aesthetics sales to XX% recovery specifically, and reminder, as market refocus whole the a effectiveness As results the console procedures as of Overall, waiting it Particularly revenue. for happen. our in increases initial the for while have accounted profitability overall utilization we encouraged versus of the on de-emphasizing business the for both that exceeded
continue the remained products faced our see challenges demand this customers despite robust We the to our have that for throughout pandemic. has
Turning improvements within a was with to have market, through results Breast Products consistent May point broader that our generally and segment low incremental April first, been our particularly June. the in
in double-digit in new accounts as set well the high declines other shows addition June We this that our sales believe product are when of this versus product share timeframe continued with clearly declined a resilience flat standout the quarter with current flat accounts. were gaining taking fact, bioCorneum, is performance the of prior and the May existing excluding at is and aesthetic of In year year-over-year penetration for we period. similar reporting that and the quarter within companies fiscal the only deeper our approximately breast XX% looking sales believe only We portfolio. space as
Importantly, we continue specifically. improving the Breast quarter with this Products into have seen trend third
tell reflects for service, and pent manufacturing is products. demand demand positions as a up a too bolus growing our throughout to trend QX for basis of a we've in segment, distribution order begun adding early number our the to of will confidence product or meet of if continue While breast ongoing this all it customer if in it
the expected, remains throughout QX. market reconstruction As strong
PMA tissue filed a highly XXX OPUS sizer we've We've we implants OPUS Sientra class new further XXX-K line also, OPUS continue We to and expander the up include, a strengthen CCs. of include win differentiated our supplement to filed accounts, in XXX-K of larger the a current initiatives a taken portfolio. breast for expander for supplement and products. Gel recently to the to OPUS for to AlloxX next-generation to sizes tissue implants sealing Gel also leverage line filed and sizers of portfolio to Sientra reconstruction also number company's portfolio extension we best a our These
Sientra. proud the second a opportunity the with We're entered during largest a quarter, very for this. organization representing It's hospital GPO X,XXX over with into the Finally, country, we significant HPG. in of national contract market hospitals,
in channel and open hospital durable a position making up, serve we're ever to to the up reconstruction than this continue in continues segment. As gains market demand share pent stronger
confidence grounded resiliency Products in our the in Breast Our strength breast is demonstrated the surgeries. for of
the Over conducted past pulse as surveys with few months, we've well several as surgeons market patients.
To still change confirmed who of get have been On COVID patient surveys have some from this recovery individual their hearing to our tapping months these the our breast the established numerous also surgeries in at sign strong demand, and been are that as our typically despite We're surveys their booked this has into over last are on they patient it we level, considering in surgery drive having breast surgeons side, initiated mind demand. time. women pandemic. make I the surgery, advance of once women augmentation over on have outlined belief up our the practice don't of several XX% breast to they Overall, that suggest customers planning assist on which programs that another augmentation call.
wherever to assistance procedures management with as leading intact sales resources our to We've partnerships plastic organization help the of cycles and most best the and convert provides our of up video them recently consultants call businesses. other navigating cohort tech customers drivetorecovery.com our practices new as in virtual adjustments, our patients frequently with We help meaningful societies Sientra and aesthetic to platform both class surgery their sientra.com new accelerate help making while exclusive well website. news, ramped augmentation procedures, innovative We've enabled of relaunch kept for to work face-to-face education our of we with believe times. well provides these also one programs continued our and through separate consultants customers. that patient our possible. business website, and safely announced regular as updated customers as meetings the interests completely overall up practice purpose loyal for users provide our changing plastic launched are pathways to surgery which and with to the generating episodes marketing in practices. into our date technology and of we force of This entire reconstruction developed We've Importantly,
that use upon the in the deciding process confirms of is research of one surgery. information their Our women of primary sources this
the from sales to transitioned high bifurcated on business the bioTip model refocus miraDry to tips segment. a We recurring sales. successfully consumable of Turning systems margin and
consumer of interest patient miraDry to in many While to convert into resized COVID customers retrained and pandemic, we our accounts the force miraDry were our and drive help treatments. our transitioning them sales
them additive Our in accounts are of terms the of value benefit industry newly to significantly patient, sooner before, decision we've to console strategic business Anecdotally, our from feature believe served over practice than second consultants as the the sales in they on discussed introducing extremely us our their are practice overall. for would. otherwise bioTip miraDry the We predominantly sales lifetime capital well an utilization in which trained the help core that quarter. down focus
of technology, as While with practices with quarter. miraDry recovery we V-shaped of utilization key more the exited been and were to a in re-engaging some existing particularly curve are we quarter, that where their in with international levels reopening patients pleased followed base performance have has this pre-COVID the returned markets, U.S.
in we margin measure high our consumables metrics. to by results of shift Importantly the key this business, two
These as key converting recovery by creating drive capability, selling utilization. through utilization and market by indicators expected. utilization more this bioTip recovery reflect marketing built earlier to tracking inventory. has driven of initiatives is new rapid First our been interest than well practice believe We automated initially patient our a bioTip around system as
treated second were with digital practice generated considerable US created of Weekly, the weeks and started. important the our the shared these publication. an media, macro XX these micro gained create stars program, also etcetera Magazine, over core Typically, leads strategy, In the programs treatment we including publicly awareness In from strategy XXX broad experiences generating to who miraDry and television we our number the we've for their of for to measure quarter People digital impressions that impact pickup brand. million level, addition practices top influencer tier our marketing in of reality we but at able part a over within traction
Our to working the recovery drive this treatments their accounts interest business consultants practices as convert into with are to reopen. closely
to as of XX% represented quarter, of COVID pandemic, Asia BioTip This the and approximately total markets was remained drive approximately Taiwan, with outside geographic utilization consistent our of also in revenue. the reopen U.S. with strategy. later to the expected, to system second business XX% note, first long-term the quarter revenue QX and Of supports and first better strategy the our consistent our Asian States for a to model than and being shut United this the with the The impact America, market while from that for is revenue view Korea in utilization into XX% representing addition the particular serving over closed miraDry utilization indicator focused shut during QX. down for longer down system segment. favorable came a revenue North placements in of with the was our optimal strategy
a cancellations drives will than is ahead, As our still more than segment if sufficient within and in our the marketing where we adapt to ability category. diligently leader to further recovery. fare a from encouraged to that, the trajectory continue in inventory medicine it we how a this we bioTips focused spread solutions, support already a demand. all with on With elective from be remind for over mix of surgeons and around there of adapt COVID margin Review, quickly remains unique in plastic to Sientra result our a before. we shift aesthetic It successful. nimbleness Paul been towards said higher to turn - hyper in certified leading will continue transfer to look risk market continue I other uncertainty due to to macro establish in to wave shift emerge telehealth QX, forecasted initiatives if me and like to demand. support that we programs let market extremely more procedures expect leverage and market while patient the and Paul. and We'll will we the believe Financial to the All That would aesthetic have to seen as benefit board share of have us certified professional our and mitigate work gains significant
